ANSI/HL7 V3 ECG, R 1-2004
健康等级7第3版标准:规定研究.带注释的ECG.发行1

HL7 Version 3 Standard: Regulated Studies - Annotated ECG, Release 1

ANSI/HL7 V3 ECG, R 1-2004 发布历史

Clinical trials on candidate drug products often collect biological data from trial subjects as waveforms or algorithmic representations of those waveforms. After the data have been collected, derived measurements such as QT interval are used to draw conclusions about the safety and effectiveness of the candidate drug. Standards exist for transmitting these derived data and their analysis results from the trial sponsor to the regulatory agencies; but these submissions have not historically included representation of the waveforms, or have at best included an image of the device-generated paper waveform. A new request to include the digital waveform, the algorithmic representations, and the annotations identifying the relevant landmarks (e.g. QRS-wave onset, T-wave offset) that support derived ECG measurements has been proposed by the US FDA. This specification will be used to package such annotated digital waveform data produced by an ECG analysis system for transmission from trial sponsor to a regulatory agency. In no case would a waveform recording device be required to communicate its direct waveform readings using this specification.

ANSI/HL7 V3 ECG, R 1-2004由美国国家标准学会 US-ANSI 发布于 2004。

ANSI/HL7 V3 ECG, R 1-2004 在中国标准分类中归属于: C07 电子计算机应用，在国际标准分类中归属于: 35.240.80 信息技术在医药卫生技术中的应用。

ANSI/HL7 V3 ECG, R 1-2004的历代版本如下：

• 2004年 ANSI/HL7 V3 ECG, R 1-2004 健康等级7第3版标准:规定研究.带注释的ECG.发行1

非常抱歉，我们暂时无法提供预览，您可以试试： 免费下载 ANSI/HL7 V3 ECG, R 1-2004 前三页，或者稍后再访问。

注意： 点击下载后，生成下载文件时间比较长，请耐心等待......

标准号

ANSI/HL7 V3 ECG, R 1-2004

发布日期

2004年

实施日期

废止日期

无

中国标准分类号

C07

国际标准分类号

35.240.80

发布单位

US-ANSI

适用范围

Clinical trials on candidate drug products often collect biological data from trial subjects as waveforms or algorithmic representations of those waveforms. After the data have been collected, derived measurements such as QT interval are used to draw conclusions about the safety and effectiveness of the candidate drug. Standards exist for transmitting these derived data and their analysis results from the trial sponsor to the regulatory agencies; but these submissions have not historically included representation of the waveforms, or have at best included an image of the device-generated paper waveform. A new request to include the digital waveform, the algorithmic representations, and the annotations identifying the relevant landmarks (e.g. QRS-wave onset, T-wave offset) that support derived ECG measurements has been proposed by the US FDA. This specification will be used to package such annotated digital waveform data produced by an ECG analysis system for transmission from trial sponsor to a regulatory agency. In no case would a waveform recording device be required to communicate its direct waveform readings using this specification.